Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study
Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...
Brand Name : PF614-MPAR
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 25, 2023
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Talphera Enrolls First Patient in Trial for Nafamostat in Extracorporeal Circuit
Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.
Brand Name : Niyad
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
Details : Niyad (a lyophilized formulation of nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Brand Name : Niyad
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2023
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $26.3 million
Deal Type : Private Placement
Details : The net proceeds will be used to advance Niyad (nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Brand Name : Niyad
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 21, 2023
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $26.3 million
Deal Type : Private Placement
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...
Brand Name : PF614-MPAR
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : PF614-MPAR (oxycodone prodrug) is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. This partnership serves as validation of the mission and ultimately the platforms.
Brand Name : PF614-MPAR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 31, 2022
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation.
Brand Name : Niyad
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2022
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Part A of the trial evaluated three dose levels of PF614 showed positive review from the Phase 1b tria, independent Safety Review Committee allowed the trial to proceed to the next dose level.
Brand Name : PRF06104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2022
Lead Product(s) : Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC)...
Brand Name : LTX-608
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Covistat will present a summary of its findings that it believes demonstrate the ability of nafamostat, delivered to airways, to inhibit SARS-CoV-2 viral infection and increase mucocilliary clearance in the human airway.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 07, 2021
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?